Published data on elderly endometrial cancer
| Author/year | No | Study population | RT dose (Gy) | Survival (%) | Toxicity | Comment |
| Fiorentino, 201321 | 35 | >65 years | 45–50.4 Gy ±VBT boost (10–15 Gy) | 2 y PFS: 69 2 y OS: 80 | No ≥grade 3 GIS, GUS or hematological toxicity. | Co-morbidity did not affect PFS and toxicity |
| Eggemann, 201712 | 1550 | <60 years 61–70 years 71–80 years ≥81 years | N/A | 10 y OS: <60 y: 81.4 61–70 y: 64.4 71–80 y: 44.1 ≥81 y: 42.4 | N/A | Elderly patients with endometrial cancer are probably undertreated in comparison with their younger counterparts |
| Torgeson, 201719 | 48 871 | 18–79 years ≥80 years | N/A | 5 y OS (RT vs no RT) 18-79 y (79.8 vs 75) ≥80 y (10.3 vs 16.2) | N/A | Patients with EC over age 80 have similar oncologic surgery as younger women; but are less likely to receive adjuvant RT |
| Rovirosa, 20183 | 438 | <65 years 65–80 years ≥ 80 years | EBRT: 44–50 Gy VBT: 10–26 Gy | ≥65 years had a worse outcome | Late toxicities were similar. Grade 3 to 4 GIS higher in ≥80 year olds | Grade 3–4 small bowel toxicity was higher in elderly patients |
| Benito, 201922 | 170/1799 (≥80 y/whole) | <80 years ≥80 years | N/A | CSS: <80 y: 61.4 m ≥80 y: 226 m | N/A | Elderly patients with EC less likely to receive optimal treatment |
| Rauh-Hain, 20152 | 20 468 | <55 years:14.9% 55–54: 31.1% 65-4:31.1% 75–84: 18.8% ≥85: 4.3% | N/A | Median OS <55y:67.3 m 55–54: 35.4 m 65-74:28.6 m 75–84: 20.5 m ≥85: 15.4 m | N/A | Elderly patients are less likely to receive optimal treatment |
| Gayar, 201120 | 675 | ≥75 years <75 years | EBRT: 44–50.4 Gy VBT: 37.5 Gy | 5 y CSS: 91 vs 96 10 y CSS 89 vs 93 | N/A | Age ≥75 years alone may not be an independent significant prognostic factor affecting tumor recurrence |
| Current study | 912 | 65-74 years ≥75 years | EBRT: 41.4–60 Gy VBT: 12–35 Gy | five y CSS:79.8 vs 74.3 five y PFS: 67.5 vs 57.8 PFS. | Age did not influenced RT-related toxicity | Older elderly (age ≥75 years) patients with EC had worse PFS than their younger old counterparts (age 65–74 years). Age was not a significant prognostic factor for cause-specific survival or tumor recurrence |
CSS, cause-specific survival; EBRT, external beam radiotherapy; EC, endometrial cancer; GIS, gastrointestinal system; GUS, genitourinary system; OS, overall survival; RT, radotherapy; VBT, vaginal brachytherapy.